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Background: Homeobox (HOX) genes deregulation has been largely implicated in the development of human
leukemia. Among the HOXB cluster, HOXB1 was silent in a number of analyzed acute myeloid leukemia (AML)
primary cells and cell lines, whereas it was expressed in normal terminally differentiated peripheral blood cells.
Methods: We evaluated the biological effects and the transcriptome changes determined by the retroviral
transduction of HOXB1 in the human promyelocytic cell line HL60.
Results: Our results suggest that the enforced expression of HOXB1 reduces cell growth proliferation, inducing
apoptosis and cell differentiation along the monocytic and granulocytic lineages. Accordingly, gene expression
analysis showed the HOXB1-dependent down-regulation of some tumor promoting genes, paralleled by the
up-regulation of apoptosis- and differentiation-related genes, thus supporting a tumor suppressor role for HOXB1 in
AML. Finally, we indicated HOXB1 promoter hypermethylation as a mechanism responsible for HOXB1 silencing.
Conclusions: We propose HOXB1 as an additional member of the HOX family with tumour suppressor properties
suggesting a HOXB1/ATRA combination as a possible future therapeutic strategy in AML.
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HOX genes form a subset of the larger family of homeo-
box genes [1], encoding transcription factors with a con-
served 60 amino-acid, helix-turn-helix DNA-binding
domain, known as homeodomain. Human HOX genes are
organized on different chromosomes in four clusters A, B,
C and D, consisting of nine to twelve tandem genes [2].
Although firstly identified as morphogenetic regulators
during embryonic development [3], many evidences have
shown that HOX containing genes play also a significant
role in normal and leukemic haematopoiesis [4]. In par-
ticular, in primitive CD34+ populations HOXB cluster
genes are coordinately transcribed during differentiation
of myeloid, erythroid [5,6] and lymphoid cells [7]. Also
some HOXB genes have been associated with specific
functions and stages of the hematopoietic maturation:
overexpression of HOXB4 has been shown to favour self-* Correspondence: alessandra.care@iss.it
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reproduction in any medium, provided the orrenewal of more primitive populations over differentiation
[8], whereas HOXB6 expression is required for normal
granulo- and monocytopoiesis and its deregulation associ-
ated with a maturation block [9]. HOX genes as HOXA9,
HOXC11 and HOXD13 have been implicated in chromo-
somal translocations associated with myeloid leukemia
where they are fused with the nucleoporin gene NUP98
[10]. Expression profiles of pediatric AMLs obtained by
Real-time PCR arrays revealed a novel signature of HOX
down regulated genes, including HOXB1 which results
significantly repressed (mean values 23.5 in normal con-
trols vs 0,8 in AMLs) [11]. Even so the authors did not
discuss its tumor suppressor role. Other HOX genes, as
HOXA5 in breast cancer, have been described as tumor
suppressor genes [12,13]. In addition HOXA5 loss of ex-
pression, due to promoter hypermethylation, has been also
suggested to arrest normal differentiation in AML [14].
Recently the first genome-wide survey of the DNA me-
thylome performed in sporadic pituitary adenomas dem-
onstrated the association between increased methylation
of HOXB1 and its significantly reduced transcription [15].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Petrini et al. Cancer Cell International 2013, 13:101 Page 2 of 13
http://www.cancerci.com/content/13/1/101In the present study we showed that HOXB1 was ex-
pressed in normal lymphocytes, erythrocytes, granulocytes
and monocytes as well as in human multipotent CD34+
cells purified from peripheral blood of healthy donors,
whereas it was not detectable in a number of analyzed pri-
mary AML blasts and leukemic cell lines. The deficiency
of HOXB1 in leukemic cells, in contrast with the reported
wide spread expression of other HOXB genes in AMLs
[16], prompted us to investigate whether its enforced ex-
pression could restore any biological function pushing the
leukemic blasts towards apoptosis and/or differentiation.
Moreover, as it is known that epigenetic deregulation of
critical genes can contribute to leukemogenesis [17], we
evaluated HOXB1 gene silencing as a consequence of pro-
moter CpG island hypermethylation or histones acetyl-
ation in the HL60 cell line. Finally, trying to dissect the
molecular pathways possibly triggered by HOXB1, we
searched its downstream genes by using an Atlas Human
Cancer macroarray.Materials and methods
Cells and cell cultures
The leukemia cell lines, including promyelocytic HL60
and NB4, myeloblastic AML193, monocytic U937, erytro-
blastic K562 and the lymphoid T cell Peer and CCRF-CEM,
were grown in RPMI 1640 medium (Gibco Invitrogen,
Grand Island, NY), supplemented with heat-inactivated
fetal bovine serum (FBS) (HyClone, Logan, Utah). HL60
cell line was also grown in the presence of differentiation
factors: all trans retinoic acid (ATRA) (Sigma-Aldrich, St.
Louis, MO) at 10-7 M and 1α,25 dihydroxyvitamin (VitD3)
(Sigma-Aldrich, St. Louis, MO) at 10-8 M, over a period of
7 or 11 days of culture, respectively. When indicated
HL60 cells were also treated with Z-Val-Ala-DL-Asp
(OMe)-fluoromethylketone (z-VAD) (Bachem, Bubendorf,
Switzerland) 25 μM alone or in combination with ATRA.
The human teratocarcinoma (NT2D1) cell line, utilized as
a positive control of HOXB1 expression, was grown in
DMEM medium, 10% FBS supplemented and induced to
differentiate by ATRA 10-7 M over a period of 9 days.
Cryopreserved cell samples obtained from a group of
twelve patients with acute myeloid leukemia were stud-
ied and subclassified according to the FAB nomenclature
(staged from M1 to M6) and cytogenetic analysis (7CN-
AML lacking major translocation, 3INV16 and 2 t:15,17)
[see Ref. 9]. The original samples (two for each group)
contained a range of 20 to 500×106 cells and >80% of
blastic infiltration. Leukocytes were isolated by Ficoll-
Hypaque density centrifugation. Normal granulocytes,
monocytes/macrophages, lymphocytes and erythroblasts
were obtained from peripheral blood of healthy donors.
CD34+ progenitor cells were purified from peripheral
blood as reported [18].Retroviral gene transduction
The HOXB1 cDNA encompassing its complete coding
sequence was cloned into the retroviral vector LXSN as
LB1SN; the LXSN empty vector was always used as an
internal control [19]. AML193, U937, NB4 and HL60
cell lines were transduced with the LXSN empty vector
and with LB1SN helper-free virus containing superna-
tants. Cells were treated twice for 4 hr with undiluted
packaging cell supernatants in presence of 8 μg/ml of
polybrene. Infected target cells were grown for 48 hr
and then selected with G418 (0.8 mg/ml). As the ectopic
expression of HOXB1 in AML193, U937 and NB4 cell
lines was apparently lost in the first days after selection
(see Additional file 1: Figure S1 and not shown), the sub-
sequent functional studies were performed on the sole
HL60 cell line.
RNA analysis
HOXB1 expression was evaluated either by traditional
or Real-time RT-PCR. For the traditional technique rela-
tive quantifications were done by densitometric analysis
after GAPDH samples normalization. When indicated
PCR products were verified by southern blotting using
an internal probe. Negative samples were confirmed after
40 amplification cycles.
Real-time RT–PCR was performed by the TaqMan
technology, using the ABI PRISM 7700 DNA Sequence
Detection System (Applied Biosystems, Foster City, CA)
as reported [19]. Commercial ready-to-use primers/probe
mixes (Assays on Demand Products, Applied Biosystems)
are listed: HOXB1: #Hs00157973_m1; early growth re-
sponse 1 (EGR1): #Hs00152928_m1; fatty acid synthase
(FASN): #Hs00188012_m1; mouse double minute 2
homolog (MDM2): #Hs00234760_m1; programmed
cell death 10 (PDCD10): #Hs00200578_m1; caspase2
(CASP2): #Hs00154240_m1; non metastatic cells 1
protein (NME1): #Hs00264824_m1; secreted protein
acidic and rich in cysteine (SPARC): #Hs00234160_m1,
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) #H
s4326317E.
cDNA expression array
Commercially available cDNA expression arrays (Atlas
Human Cancer cDNA expression array 1.2, containing
1176 human genes involved in cancer, Clontech, Mountain
View, CA) were used to compare gene expression of
LXSN- and HOXB1-transduced HL60 cell line. Arrays,
twice repeated, were screened according to the manu-
facturer’s protocol and as reported [19]. The gene list of
Table 1 was obtained by using 1.6 as cutoff value.
Western Blotting
Protein analysis was performed by immunoblot according
to standard procedures. The primary antibodies used
Table 1 Differentially expressed genes evaluated by macroarray in HL60/HOXB1 vs HL60/LXSN
Gene GenBankID Function Ratio HOXB1/LXSN qRT-PCR ratio
BRCA2 U43746 Oncogenes & tumor 0,10
CCNI D50310 Cell cycle regulators 0,34
EGR1 X52541 Transcriptional regulators 0,21 0,02
FASN S80437 Fatty acid/Lipid metabolism 0,13 0,25
FBP2 U69126 Hydrolases/carbohydrate biosynthesis 0,50
MDM2 Z12020 Oncogenes/Apoptosis assoc. proteins 0,31 0,5
OAS1 M11810 NucleotidylTransferases 0,06
SKY D17517 Protein kinases receptors 0,58
SOD1 K000454 Antioxidant/Oxidoreductases 0,65 0,7
TNFRSF1A L41690 Growth factor receptors 0,06
AKAP1 X97335 Mitochondrial targeting of proteins 1,94
CASP2 U13021 Cysteine proteases/Caspases 1,63 1,4
CCND3 M92287 Cell cycle regulators 4,54
CDC37 U63131 Cell cycle regulators 7,03
CRM1 Y08614 Transporter proteins 2,43
MAPRE1 U24166 Cytoskeleton Regulators 1,62
EIF3B U78525 Initiation of translation factors 2,49
ERBB3 M29366 Receptor tyrosine kinases 3,00
JNK2 L31951 Intracellular kinase network members 1,93
KPNB1 L38951 Transporter proteins 1,59
NME1 X17620 Kinases/ Transferases 2,62 1,4
PDCD10 AF022385 Apoptosis-associated proteins 3,50 1,4
PTP4A1 U48296 Protein tyrosine phosphatases 2,00
RPS5 U14970 Ribosomal proteins 3,00
SPARC J03040 Matrix-associated proteins 2,85 1,5
ST13 U28918 HSC70-interacting proteins 2,00
TRAM X63679 Secreted protein translocation 2,55
Differential gene expression was confirmed by RT-PCR when indicated. The reported ratio indicates the observed fold increase or decrease of the HL60/HOXB1
gene expression over HL60/LXSN. Cut-off value 1,6.
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Products, Berkeley, CA); anti-apoptotic peptidase activat-
ing factor 1 (APAF1) and anti-BCL2-associated X protein
(BAX) (BD, San Jose, CA); anti-histone deacetylase 4
(HDAC-4) and anti-caspase3 (CASP3) (Cell Signaling
Technology, Beverly, MA); anti-B-cell CLL/lymphoma 2
(BCL2) and anti-myeloid cell leukemia1 (MCL-1) (Santa
Cruz Biotechnology, Dallas, TX) and mouse monoclonal
anti-actin (actin) (Calbiochem, La Jolla, CA).In vitro growth and cell cycle assays
The proliferative rate of LXSN- and HOXB1-transduced
cells was evaluated by a XTT-based colorimetric assay
(Roche Molecular Biochemicals, Mannheim, Germany)
[19] and the Trypan-Blue exclusion dye test. Cell cycle
analysis was performed using a CycleTEST™ PLUS Kit(BD, San Josè, CA) on HL60 cells, transduced or not
with HOXB1.Apoptosis assay
For each sample 105 cells were incubated and stained
according to standard procedures (TACS™ AnnexinV-FITC
apoptosis detection Kit) (R&D Systems Inc, Minneapolis,
MN). Results were expressed as total absolute percentages
of AnnexinV+, Annexin+/PI+and PI+ gated cells.
Apoptosis was also evaluated by the ApoONE Ho-
mogenous Caspase 3/7 Assay. A spectrofluorometer 96
wells plate reader (Wallac VICTOR2, Turku, Finland) was
used for measuring the fluorescence of 5×104 cells/well of
both HL60/LXSN and HL60/HOXB1. Cells were kept in
1% FBS or in 10% FBS. As a control, cells were grown in
the presence of staurosporine at 200nM for 1 hr.
Petrini et al. Cancer Cell International 2013, 13:101 Page 4 of 13
http://www.cancerci.com/content/13/1/101Cell surface markers and morphological analysis
To evaluate the granulocytic and monocytic differenti-
ation capacities, LXSN- and HOXB1- transduced HL60
cells were grown in vitro up to 7 or 11 days in the pres-
ence of 10-7 M ATRA or 10-8 M VitD3, respectively.
Cells were then analyzed for cell surface markers and
morphology. Specifically, the cells were labelled with
anti-CD11b and anti-G-CSF receptor (G-CSFR) (for G-
lineage differentiation), double stained with anti-CD14/
anti-CD11b (for M-lineage differentiation) (Pharmingen,
San Diego, CA) and subjected to FACS analysis (FACS
Scan Becton Dickinson, San Diego, CA).
Cell morphology was evaluated on May-Grünwald-Giemsa
stained slides according to standard criteria. Classification
includes blasts, promonocytes and promyelocytes as inter-
mediate cells, and monocytes, myelocytes and beyond as
mature cells. Three separate experiments were analyzed
by two independent blind observers.
Epigenetic analysis of HOXB1 promoter
The methylation status of CpG islands of HOXB1 pro-
moter was evaluated by the SABiosciencesEpiTect Me-
thyl DNA Restriction kit (Qiagen, Gaithersburg, MD)
[20]. HOXB1 CpG island location was Chr17:46607804–
46608390. Related RefSeq ID: NM_002144 (HOXB1).
Briefly, 250 ng of DNA-RNA free, extracted by the
DNeasy blood and tissue KIT (Qiagen), were digested
in four equal reactions with no enzymes, methylation-
sensitive enzyme, methylation-dependent enzyme, or both
enzymes according to the manual instructions (EpiTect®
Methyl qPCR Assay Handbook, www.qiagen.com). To de-
termine the relative amounts of hypermethylated (HM),
intermediately methylated (IM) and unmethylated (UM)
DNAs, the products of these reactions were amplified by
SABiosiences EpiTect Methyl qPCR primer assay for hu-
man HOXB1 (MePH22204-2A). To analyze the effects of
demethylation on HOXB1 gene expression, we treated
HL60 cells (0,5×106/ml) for 1 up to 5 days with the
demethylating agent 5-Azacytidine (5-AzaC) at 1 μM and
5 μM concentrations (Sigma-Aldrich, Saint Louis, MO),
replacing medium and adding new 5-AzaC every 48 hrs.
Moreover, to evaluate HOXB1 epigenetic regulation by
the histones acetylation-deacetylation mechanisms, we
treated the HL60 cells (0,5×106/ml) with 100 or 600 ng of
the histone deacetylase inhibitor Trichostatin A (TSA)
(Sigma-Aldrich) for 48 and 72 hr [21]. Following all the
above mentioned treatments, we searched for HOXB1
mRNA re-expression in HL60 cells by RT-PCR.
Statistical analysis
All the experiments were repeated at least three times,
unless otherwise stated. Reported values represent mean ±
standard errors (S.E). The significance of differences
between experimental variables was determined usingparametric Student’s t-test with P < 0.05 deemed statisti-
cally significant. P-values relative to HOXB1-transduced
cells were always referred to LXSN-transduced cells.
Results
HOXB1 is downregulated in leukemic cells
We evaluated the endogenous expression of HOXB1 in a
panel of representative primary acute myeloid leukemia
(AML) cells, staged from M1 to M6, and some stabilized
leukemic cell lines (U937, HL60, AML193, NB4, K562,
CEM and PEER). As normal controls, we utilized termin-
ally differentiated cells, including granulocytes, monocytes,
macrophages, erythroblasts and lymphocytes, as well as
CD34+ progenitors from peripheral blood.
As determined by qReal-Time and traditional RT-PCR,
HOXB1 was barely or not expressed in all the examined
neoplastic cells, even after 40 cycles of amplification
(Figure 1a), whereas it was detectable, at RNA and protein
levels, in normal cells purified from peripheral blood and
in CD34+ progenitors (Figure 1b and c). Among the
AMLs the exceptions, showing HOXB1 expression, were
the M6 staged erythroleukemias and the K562 cell line,
possibly in agreement with their predominant erythro-
blastic cells component (Figure 1a and b). In all the exper-
iments a 9 days ATRA-induced teratocarcinoma NT2/D1
sample was included as a positive control (Figure 1a, b, d
and e).
HOXB1 restored expression induces apoptosis and cell
death in HL60
To investigate the functional role of HOXB1, we selected
the AML193, U937, NB4 and HL60 cell lines as models
for gene transduction. To this end was utilized the retro-
viral vector LB1SN and the correct transcription and
translation of HOXB1 mRNA and protein were con-
firmed by qReal-Time RT-PCR and Western blot ana-
lysis (Figure 1c-d-e, Additional file 1: Figure S1 and not
shown). Unfortunately, as the enforced expression of
HOXB1 resulted quickly lost in AML193, U937 and
NB4, the sole HL60 cell line was exploitable to deter-
mine whether HOXB1 overexpression might actually
affect the biological properties of HL60 cells.
We then performed some representative in vitro func-
tional assays in high (10%) and low (1%) serum condi-
tions. In order to evaluate the proliferative rate, cells
were initially seeded at 1×105/ml and monitored up to
7 days when a significant reduction of cell growth (equal
to 70%) was visible in HOXB1-expressing cells, regard-
less of serum concentration (Figure 2a and data not
shown). Looking for the cause of such reduction, we
compared the total apoptotic rates (including annexin+,
annexin+/PI+ and PI+ cells) detectable in HOXB1- and
LXSN-transduced cells. Interestingly, in HOXB1/HL60
cells we observed an increase from 14% to 22% in high
Figure 1 HOXB1 expression analysis. Real time RT-PCR in a panel of leukemic cell lines (U937, HL60, AML193, K562, CEM, Peer) and in primary
cells from patients staged from M1 to M6 AMLs (a). Representative RT-PCR in lymphocytes, granulocytes, monocytes, erythroblasts and CD34+ from
normal peripheral blood, and in M6 erythroleukemia (b, bottom). The relative quantifications are reported as the ratio HOXB1/GAPDH (b, top). HOXB1
protein expression in normal peripheral blood cells compared to HL60/HOXB1 cells (c). Real time RT-PCR in LXSN- and HOXB1-transduced HL60
cell lines (d). Western blot analysis of HOXB1 (e); actin was used for normalization. NT2/D1 cells, treated with ATRA for 9 days, were utilized as
positive controls.
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from a basal 54% up to 77%, in low serum cell cultures
(Figure 2c).
To identify which members were mainly involved in
the HOXB1-dependent apoptotic process, we analyzed
by western blot a number of apoptosis related factors in
HOXB1- vs LXSN- HL60 cells kept in 1% serum con-
dition. Results showing the functional activation of
caspase 3&7 (> 4 fold) (Figure 2d) were confirmed by
the induction of the cleaved form of CASP3 protein(Figure 2e left). The caspase activating factor, stauros-
porine (200 nM) was included as a positive control
(Figure 2d).
In addition the role of HOXB1 was sustained by the
differential expressions of the antiapoptotic Bax and the
proapoptotic Mcl1 proteins, respectively induced and
downregulated by HOXB1. The Bax/Bcl2 ratio, doubled
by HOXB1, was also indicative of a more apoptogenic
balance (ratio Bax/Bcl2 0.7 in LXSN- and 1.3 in
HOXB1-HL60) (Figure 2e right). Finally, in the HOXB1
Figure 2 Effects of HOXB1 restored expression in HL60 cell line. Analysis of cell growth (a) and percentage of apoptotic & dead cells, as
evaluated at day 7 of culture by the Annexin/PI analysis system in 10% (b) and 1% (c) FBS, *p < 0.01. Activation of CASPASE 3/7 in LXSN- and
HOXB1-transduced HL60 cells in low serum condition and in presence of 200 nM staurosporine in 10% FBS (d), **p <0.005. Western blot analysis
of pro- and active CASPASE 3 and APAF1 (e left) and BCL-2, BAX and MCL1 proteins (e right). Actin was used for normalization. Cell cycle
analysis in LXSN- and HOXB1-transduced HL60 cells (f).
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proapoptotic factor APAF1 (Figure 2e left).
In view of the lack of significant differences in the cell
cycle analysis of HOXB1- respect to LXSN-transduced
cells (Figure 2f ), we could consider the apoptotic process
as the main mechanism underlying the HOXB1-dependent
decrease of cell growth.
The HOXB1-dependent effects in the HL60 cultures
were then analyzed upon treatment with differentiating
concentrations of all-trans-retinoic acid (10-7 M ATRA)
or 1,25-dihydroxyvitamin D3 (10-8 M VitD3). Growth
curves showed significant reductions of the HL60/
HOXB1 cell growth respect to control cells in both cul-
ture conditions (Figure 3a and b). The percentage of
apoptotic plus dead cells in 10% FBS cultures monitored
for 7 days was almost doubled in HL60/HOXB1 cells
treated with VitD3 (11% vs 6%) and three-fold more with
ATRA (22% vs 7%) compared with LXSN corresponding
controls (Figure 3c). In 1% serum the higher basal per-
centage of apoptotic plus dead cells observed in the
LXSN controls was further enhanced by HOXB1, from
40% to 62% in VitD3- and from 26% to 54% in ATRA-
treated cultures (Figure 3d).HOXB1 sensitizes HL60 to ATRA- and VitD3-induced
differentiation
We studied whether HOXB1 could have any effect on
HL60 differentiation, alone or in synergy with the differ-
entiating factors ATRA or VitD3. The onset of differen-
tiation was estimated through a morphological analysis
of the cells based on the Giemsa-McGrünwald colori-
metric method, and the extent of differentiation was
measured by FACS analysis of the cell surface markers
CD11b, CD14 and G-CSFR. Although the percentage of
CD11b positive cells was increased from 24 to 41% in
LXSN- vs HOXB1-transduced cells, suggesting that
HOXB1 per se might commit cells to granulocytic differ-
entiation, the presence of HOXB1 did not seem suffi-
cient to induce clear morphological changes during the
myeloid maturation, at least in 10% serum (Figure 4a
and data not shown). Nonetheless, after 7 days of ATRA
treatment, although CD11b was highly expressed (>90%)
in both HOXB1- and LXSN-transduced cells, the mor-
phological analysis showed a higher number of terminally
differentiated granulocytes (69% vs 46%) in HOXB1-
transduced cells (Figure 4b and c). In the monocytic
condition, the CD11b+/CD14+ markers associated with
Figure 3 Effects of HOXB1 restored expression on cell proliferation and apoptotic rates. Cell growth curves in HOXB1- versus LXSN-
transduced HL60 cells in ATRA (10-7 M) inducing granulocytic differentiation (a) and VitD3 (10-8 M) inducing monocytic differentiation
(b). Percentage of apoptotic & dead cells in HOXB1- versus LXSN-transduced HL60, in high (c) or low (d) serum conditions in presence of ATRA
or VitD3. *p < 0.01; **p < 0.005.
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39%) at day 3 and 8% (from 70 to 78%) at day 11 of culture
in HOXB1- respect to LXSN-transduced cells (Figure 4d).
Cell morphology showed a HOXB1 dependent increment
in the number of terminally differentiated monocytes
paralleled by a reduced amount of blast cells at day 7
(Figure 4e and f ).
Trying to understand the HOXB1-based mechanisms
in inducing apoptosis and enhancing differentiation, we
compared the differentiation level of HL60/HOXB1 vs
control vector in presence or not of the caspase inhibitor
z-VAD and 1% of serum. Firstly, in control conditions
we confirmed the capability of HOXB1 to induce a cer-
tain degree of maturation (Figure 5a-c). Indeed, up to
day 6 of cell culture, HL60/LXSN only included undif-
ferentiated blasts, whereas approximately 40% of inter-
mediate differentiated cells were detectable in HOXB1-
expressing HL60 (Figure 5b). The percentage of CD11b
and G-CSFR positive cells was increased from 31 to 66%
and from 21 to 37% in LXSN- vs HOXB1-transduced
cells, respectively (Figure 5a). As supported in terms of
microscopic analyses and CD11b cell surface marker, the
presence of z-VAD appeared to slightly interfere withthe direct HOXB1 action. Conversely, the HOXB1-
related differences, visible in ATRA-treated cells, were
maintained by the combination with z-VAD, thus indi-
cating that HOXB1-induced sensitivity to ATRA is
maintained blocking apoptosis (Figure 5a-c). In these
experiments the addition of z-VAD seemed to be even
more effective on cell differentiation, possibly through
an accumulation of mature cells otherwise addressed to
death.
Expression analysis of HOXB1-regulated genes
In order to gain insight in the molecular mechanisms
underlying HOXB1 effects in the leukemic phenotype,
we investigated genes differentially expressed in HOXB1-
negative vs HOXB1-positive HL60 cells by probing an
Atlas Human Cancer cDNA macroarray (Table 1). The
expression level of some selected genes was confirmed
by Real-time RT–PCR (Figure 6a and b). Interestingly,
among the differentially expressed genes, we found mol-
ecules that could directly explain the reduced ma-
lignancy of HOXB1-transduced cells. Some tumour
promoting genes, related to cell growth and survival,
like the early growth response 1 (EGR1), the fatty acid
Figure 4 Surface markers and morphological analysis in LXSN- and HOXB1-transduced HL60. CD11b positive cells at day 0, 3 and 7 of
ATRA (10-7 M) treatment (a). Morphological analysis (b) and representative pictures (c) of ATRA-treated granulocytic-like cells. CD11b/CD14
double positive cells at day 0, 3 and 11 of VitD3 (10-8 M) treatment (d). Morphological analysis (e) and representative pictures (f) of VitD3-treated
monocytic-like cells. Cells were detected by the Giemsa-McGrünwald colorimetric method. Arrowheads indicate mature cells, long arrows blasts
and double arrows intermediate cells.
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Figure 5 Evaluation of ATRA-differentiation in presence of the apoptotic inhibitor z-VAD. Surface markers analysis of CD11b (at day 6) and
G-CSFR (after 1 hr) in LXSN- and HOXB1-transduced HL60 cells in low serum and ATRA (10-7 M), z-VAD (25 μM) and z-VAD (25 μM) + ATRA (10-7 M)
treatments (a). Morphological analysis (b) and representative pictures (c). Cells were detected by the Giemsa-McGrünwald colorimetric method.
Arrowheads indicate mature cells, long arrows blasts and double arrows intermediate cells.
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Figure 6 Differential expressions in HOXB1- versus LXSN-transduced HL60 cells. Real-time RT-PCR of EGR1, FASN and MDM2
downmodulated (a) or PDCD10, CASP2, NME1 and SPARC upmodulated (b) genes. GAPDH was used for normalization.*p < 0.01; **p < 0.005.
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log (MDM2), resulted in fact strongly down-regulated
(Table 1 and Figure 6a), whereas pro-apoptotic or tumor
suppressor genes, as the caspase2 (CASP2), the pro-
grammed cell death 10 (PDCD10), the non metastatic
cells 1 protein (NME1), and the secreted protein acidic
and rich in cysteine (SPARC) were up-regulated (Table 1
and Figure 6b).Figure 7 HOXB1 promoter methylation in HL60 versus granulocytes a
not methylated (UM), and intermediate methylated (IM) fractions (a). HM and
evaluation of HOXB1 in 5-AzaC- and TSA-treated HL60 cells compared with ly
quantitative standard. Western blotting of HDAC4 and HOXB1 in TSA-treatedHOXB1 promoter results methylated in HL60
To investigate the possible mechanisms underlying
HOXB1 downregulation in leukemic cells, we compared
the methylation status of the CpG island present on
HOXB1 promoter in HL60 and in normal monocytes
and granulocytes from peripheral blood. As shown by
three separate experiments, the hypermethylated (HM)
fraction of the HOXB1 CpG island was significantlynd monocytes. Relative percentage of DNA hypermethylated (HM),
UM in 5-AzaC 1 μM treated HL60 cells after 48 h and 72 h (b). RT-PCR
mphocytes, granulocytes and monocytes (c). GAPDH is shown as
HL60 cells (d). Actin was used as quantitative standard.
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granulocytes (97% respect to 82 and 68%) (Figure 7a). In
order to verify the actual role of methylation on HOXB1
regulation, we treated the HL60 cell line with the
demethylating drug 5-AzaC at 1 μM and 5 μM doses for
48 and 72 hrs. As the higher dose of 5-AzaC (5 μM)
strongly reduced cell proliferation, we selected 1 μM
dose for further studies. As expected, the HM fraction
resulted decreased in 5-AzaC treated cells (Figure 7b)
and its functional significance confirmed by re-expression
of endogenous HOXB1 in the same samples (Figure 7c).
On the contrary, we did not get any HOXB1 re-expression
by treating the HL60 cells with the histone deacetylase in-
hibitor TSA (100 and 600 ng) for 8 hr and 24 hrs (Figure 7c
and data not shown). As an internal control, the effective-
ness of the TSA treatment was confirmed by the decrease
of histone deacetylase 4 (HDAC4), one of the core compo-
nents of the nucleosome (Figure 7d).
Discussion
Numerous reports have catalogued differences in HOX
genes expression between normal and neoplastic cells,
but their functional relationship with the malignant
phenotype in many cases remained elusive [22]. HOX
genes are currently under evaluation in order to correl-
ate specific HOX alterations with changes in cellular
processes such as cell proliferation, differentiation and
apoptosis. Other than HOX overexpression, also HOX
downregulation has been associated with different malig-
nancies, including leukemia. Examples of tumor sup-
pressors are the homeodomain protein NKX3.1 and
HOXD10 commonly down-regulated in human prostate
cancer [23], breast tumor cells and gastric carcinogenesis
[24,25]. In addition HOXA5 expression is lost in breast
tumors [12] and HOXA genes, normally playing sup-
pressor roles in leukemia development, are frequent tar-
gets for gene inactivation [26]. Accordingly, expression
studies indicated a set of seven downregulated HOX
genes (HOXA3, A4, A5, A7, B1, B9, C9) as significantly
clustered in pediatric AMLs [11].
In this study we propose HOXB1 as an additional
member of the HOX family with tumor suppressor
properties. HOXB1 is expressed in terminally differenti-
ated blood cells (erythrocytes, granulocytes, monocytes
and lymphocytes) and in CD34+ progenitors from per-
ipheral blood, but not in primary blasts from M1 to M5
and myeloid cell lines. Our results indicate a mechanism
of CpG island promoter hypermethylation at the basis of
HOXB1 silencing in AML as demonstrated by the higher
amount of the hypermethylated DNA fraction in HL60
cells compared to normal cells. Accordingly, the demethy-
lating agent 5-AzaC was able to reactivate HOXB1 expres-
sion in HL60 cells, whereas treatment with the histone
deacetylase inhibitor TSA had no effect.Results obtained by HOXB1 gene transduction in HL60,
in agreement with the rapid counter-selection of the ec-
topic HOXB1 in AML193, U937 and NB4 cell lines
(Additional file 1: Figure S1), point to the contribution
of HOXB1 abnormal silencing to the survival of myeloid
leukemic cells.
In HL60, HOXB1 restored expression was per se able to
induce apoptosis and, in the presence of ATRA or VitD3,
to favour maturation towards granulocytic and monocytic
differentiation pathways, respectively. Of note, the HOXB1
induced differentiation, visible in ATRA-treated cells, does
not appear associated with the apoptotic process, as
shown by ATRA + z-VAD treatment.
According to our Atlas macroarray analysis, we identified
a number of HOXB1 dependent up- and down-modulated
genes. Specifically, we observed the up-regulation of some
apoptosis-related genes as CASP2, JNK2, PDCD10, SPARC
and heat-shock protein 70 kD-interacting protein (ST13).
In particular CASP2, JNK2, PDCD10, and ST13 have been
associated with mitochondrial permeabilization [27-30] and
with the induction of the apoptotic process, while SPARC
overexpression seems to play a tumor suppressor function
in some low expressing SPARC AMLs [31,32]. As in
HOXB1-transduced cells we also observed a significant
enhancement of APAF1 (Figure 2e), we suggest the in-
volvement of HOXB1 in triggering the mitochondrial as
well as caspase dependent apoptotic pathways [33], as in-
dicated by the activation of caspase 3/7 (Figure 2d,e).
Accordingly we also detected a HOXB1-dependent regu-
lation of the BCL-2 family of proteins playing a major role
in the control of apoptosis. In particular, the proapoptotic
role of HOXB1 was sustained by the induction of BAX
and the downregulation of MCL1 proteins. Moreover the
BAX/BCL2 ratio, doubled by HOXB1, was indicative to
increased cell susceptibility to apoptosis [34].
In addition, the macroarray analysis showed the HOXB1-
dependent downregulation of some antiapoptotic genes as
MDM2, FASN, the antioxidant enzyme superoxidedis-
mutase (SOD1) and the breast cancer susceptibility gene 2
(BRCA2). As the knockdown of MDM2 in p53 mutant
non-small cell lung cancer [35,36], the FASN reduced
expression in HepG2 cells [37,38] or the SOD1 down-
regulation in AMLs [39,40] can induce apoptosis, we
might suggest a HOXB1 related anticancer activity.
Nonetheless, as p53 is not expressed in HL60 cells, we
should consider the involvement of other members of
the p53 family, as p63 and p73 expressed in HL60 cells
[41]. Specifically p63 has been described to be activated
by PBX cofactors [42] and in HL60 cells we observed a
HOXB1-related induction of PBX2 (data not shown),
thus possibly suggesting the effectiveness of p63 down-
stream to HOXB1.
Finally, EGR1 displayed a striking downregulation. Al-
though deserving further studies due to its complex and
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ment with the lower tumorigenicity of HL60 cells over-
expressing HOXB1. In fact EGR1 has been reported to
play a role in prostate tumor growth and survival [43]
and its abnormal expression has been recently associated
with tumor invasion and metastasis in gastric cancer
[44]. In addition, a higher level of EGR1 has been associ-
ated with relapsing AML respect to AML at diagnosis
with a direct correlation with increased proliferation and
enhanced RAF/MEK/ERK1/2 activation [45].
In conclusion our results indicate an antineoplastic
role for HOXB1 in AMLs through its functional involve-
ment in promoting apoptosis and powering ATRA-
induced differentiation. Considering the presence of two
RARE elements at the 5′ and 3′ ends of HOXB1 [46],
we might suggest a role for HOXB1 in ATRA-mediated
anticancer activity. In this view a HOXB1/ATRA com-
bination might represent a possible future therapeutic
strategy in AML [47,48].
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